These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 12122172)

  • 1. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.
    Malucchi S; Sala A; Gilli F; Bottero R; Di Sapio A; Capobianco M; Bertolotto A
    Neurology; 2004 Jun; 62(11):2031-7. PubMed ID: 15184610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
    Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
    Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.
    Bertolotto A; Sala A; Malucchi S; Marnetto F; Caldano M; Di Sapio A; Capobianco M; Gilli F
    J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1294-9. PubMed ID: 15314118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of interferon beta: differences among products.
    Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
    J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis.
    Bellomi F; Muto A; Palmieri G; Focaccetti C; Dianzani C; Mattei M; Jaber A; Antonelli G
    New Microbiol; 2007 Jul; 30(3):241-6. PubMed ID: 17802901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
    Phillips JT; Rice G; Frohman E; Vande Gaer L; Scott T; Haas J; Eggenberger E; Freedman MS; Stuart W; Cunha L; Jacobs L; Oger J; Arnold D; Murray TJ; DiBiase M; Jethwa V; Goelz S
    Clin Ther; 2004 Apr; 26(4):511-21. PubMed ID: 15189748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies to multiple sclerosis treatments.
    Rossman HS
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S12-9. PubMed ID: 15253685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
    Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
    Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
    Cook SD; Quinless JR; Jotkowitz A; Beaton P;
    Neurology; 2001 Sep; 57(6):1080-4. PubMed ID: 11571337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the relative bioavailability of different interferon beta preparations.
    Deisenhammer F; Mayringer I; Harvey J; Dilitz E; Gasse T; Stadlbauer D; Reindl M; Berger T
    Neurology; 2000 Jun; 54(11):2055-60. PubMed ID: 10851362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
    Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
    J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS; Frohman EM; Hurwitz B; O'Connor PW; Oger JJ; Reder AT; Stevens JC
    Neurology; 2007 Mar; 68(13):977-84. PubMed ID: 17389300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.